

# Lumito and Truly Labs Take the Next Step Together Following Successful Pilot Study – Preparing for Customer Sample Analysis

**Lumito AB today announces that its collaboration with Truly Labs has resulted in the completion of a pilot study showing positive results. The next step will be validation with customer samples. The outcomes of this validation will form the basis for Truly Labs' offering of tissue analysis using Lumito's product Scizys to its customers.**

The purpose of the pilot study was to evaluate Lumito's product Scizys, together with the company's upconverting nanoparticles (UCNPs), in degenerative disease models. Degenerative disease models are used in research to simulate conditions in which tissues and organs progressively deteriorate, such as neurological or muscular diseases.

The pilot study demonstrated that Lumito's technology, compared to current methods, can extract more information from each tissue sample. This provides researchers with a clearer understanding of disease progression, since even small differences in disease markers within the tissue can be crucial, and enables more confident decision-making in the development and evaluation of new drugs.

"We are very pleased with the positive results from the pilot study. Moving on to customer samples is an important milestone and paves the way for Truly Labs to offer Scizys testing to their clients. At the same time, we continue to optimise the amount of information can be extracted from each sample, strengthening the value of our technology for both researchers and drug developers," says Sanna Wallenborg, CEO of Lumito.

"By using Lumito's UCNP technology, we observe improved sensitivity in our measurements, which is very promising. It enables automated and more precise quantification, reinforcing our current manual and semi-quantitative evaluation methods, and thus allows us to deliver more reliable and consistent results. We are confident that this method will add significant value for our customers," says Charlott Brunmark, CSO of Truly Labs.

This work follows the strategic partnership initiated with Truly Labs in December 2024 and marks the next stage in our collaborative development. The next step is to begin testing with customer samples, in collaboration with Truly Labs, aiming to validate the pilot study results and further enhance the utility of Lumito's technology in practical research settings.

**For further information, please contact:**

---

Sanna Wallenborg, CEO Lumito

E-mail: [sw@lumito.se](mailto:sw@lumito.se)

Ph: +4670-870 01 68

**About Lumito**

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. [www.lumito.se/en/](http://www.lumito.se/en/)

**About Truly Labs**

Truly Labs AB is a Contract Research Organization (CRO) providing customized in vitro and in vivo services to its customers. Truly Labs was founded in January 2015 as a subsidiary of Truly Translational AB. The Truly Labs' team has a solid track record with scientific and experimental expertise and experience from drug research & development in both large pharma and biotech, and extensive experience of working with both small molecules and biologics. Truly Labs' key therapeutic areas are inflammation, respiratory diseases, oncology and autoimmune diseases where we offer state of the art in vitro and in vivo technologies.

**Attachments**

[Lumito and Truly Labs Take the Next Step Together Following Successful Pilot Study – Preparing for Customer Sample Analysis](#)